Max Colao Shares How OncoVerity is Pioneering Oncology Solutions

Max Colao's career in the biotech industry spans more than 3 decades, with a significant portion of his time spent at industry giants like Amgen and Alexion. Now, as the CEO of OncoVerity, a Colorado-based biotech company, Colao is leading the charge in developing personalized cancer treatments that leverage computational biology and machine learning. In this interview with Pharmaceutical Executive, he gets into the history of OncoVerity, the company's progress in clinical trials, and his vision for the future of oncology care, driven by a deep personal commitment to making a difference in the lives of patients.

• 00:33 - Colao's journey in the pharmaceutical landscape, including his time at Amgen and Alexion
• 02:18 - History and approach of OncoVerity, a biotech company focused on cancer treatment
• 04:53 - OncoVerity's clinical trials, including the COVID-19 trial
• 06:35 - Impact of the Inflation Reduction Act on the biotech landscape
• 09:45 - Utilization of machine learning and AI in cancer treatment development
• 12:47 - Colao's desired legacy as a leader in oncology and rare disease
• 14:09 - Excitement about the future of oncology care